Q1 2025 · 13F-HR
GENERAL ATLANTIC, L.P.holdings as filed
Filed 2025-05-14 · accession 0000950142-25-001365
$2.98B
Reported value
15
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 01625V104 | ALHC | ALIGNMENT HEALTHCARE | $1.14B | 38.1% | 60,993,323 | Common | SOLE |
| G29018101 | DLO | DLOCAL | $533.0M | 17.9% | 63,906,695 | Common | SOLE |
| G98239109 | XP | XP, INC | $407.2M | 13.7% | 29,617,733 | Common | SOLE |
| 01644J108 | ALKT | ALKAMI | $253.2M | 8.50% | 9,645,318 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS | $211.9M | 7.11% | 5,233,989 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS | $139.2M | 4.67% | 9,681,818 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS | $118.2M | 3.97% | 7,531,252 | Common | SOLE |
| 29882P106 | EWCZ | EUROPEAN WAX CENTER | $51.8M | 1.74% | 13,110,492 | Common | SOLE |
| G7709Q104 | RPRX | ROYALTY PHARMA | $46.7M | 1.57% | 1,500,000 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE | $37.4M | 1.26% | 1,261,684 | Common | SOLE |
| M8216R109 | RSKD | RISKIFIED | $24.6M | 0.83% | 5,324,998 | Common | SOLE |
| 00445A100 | — | ACELYRIN | $6.7M | 0.22% | 2,695,327 | Common | SOLE |
| 005329107 | ADAG | ADAGENE | $5.8M | 0.20% | 3,825,952 | Common | SOLE |
| 21077C305 | 5ZZ0 | WISH | $4.3M | 0.14% | 609,616 | Common | SOLE |
| 39957D201 | GROV | GROVE COLLABORATIVE | $3.3M | 0.11% | 2,474,859 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.